Introduction
Anaplastic lymphoma kinase 1 (ALK-1) is a member of the insulin receptor tyrosine kinase family (RTK) [
1]. Members of this family include α and β type PDGF receptors, EGF receptor, HER2/neu, insulin and IGF-1 receptors which regulate cellular growth and may trigger neoplastic transformation when mutated, translocated, or expressed aberrantly [
1-
3]. ALK-1 first was found to be associated with the (2; 5)(p23; q35) chromosome translocation in Ki-1 lymphoma or anaplastic large cell lymphoma (ALCL) [
4]. The same translocation has also been associated with Hodgkin lymphoma [
1]. Multiple mutations involving the ALK gene have since been identified in ALCL. ALK mutations have also been implicated in the pathogenesis of rhabdomyosarcoma [
5], inflammatory myofibroblastic pseudo tumor [
6], neuroblastoma [
7] and non-small cell lung Cancer [
8]. In this article, we discussed common ALK mutations and provided a review of ALK-1 Inhibitors that are currently in clinical use or under clinical development.
ALK-1 mutations and oncogenesis
Multiple mutations involving the ALK gene located on 2p23 have been described. The first and prototype of these mutations has been the NPM-ALK mutation caused by translocation (2; 5)(p23; q35) [
4,
9,
10]. This mutation fuses the nucleophosmin (NPM) gene with the ALK gene and was first described in Ki-1 Lymphoma. Ki-1 Lymphoma is a distinct subset of large cell lymphomas that are characterized by CD-30 (Ki-1 antigen) positivity. CD30 is a transmembrane protein which belongs to the nuclear growth factor superfamily and is thought to be involved in ligand binding [
4]. NPM encodes for the nucleophosmin protein that is localized to the nucleolus and involved in ribosomal assembly. It is postulated that it provides positive feedback to cell growth [
11,
12]. The NPM-ALK fusion gene encodes a chimeric receptor tyrosine kinase (RTK) that is de-regulated and constitutionally activated. This leads to activation of phospholipase C-γ (PLC-γ) [8]. Activation of PLC-γ leads to growth factor independent proliferation of lymphocytes. Another mechanism that has been elucidated is the hyperphosphorlyation of p80. Fusion of ALK with NPM leads to hyperphosphorylation of p80 and its constitutional activation. This constitutionally active p80 is localized to the cytoplasm and catalyzes the phosphorylation of SH2 domain-containing transforming protein (SHC), an adaptor protein, and insulin receptor substrate 1 (IRS-1) with downstream effects on RAS and epidermal growth factor receptor (EGFR) pathways [
12].
Other mechanisms that have been unearthed mainly occur through the Jun set of proteins [
13,
14]. Jun (cJun, JunB and JunD) are members of the activated protein 1 (AP-1) transcription factor complex. cJun is regulated by the NPM-ALK tyrosine kinase via pathologic phosphorylation and subsequent activation of cJun N-terminal kinase (JNK), the protein kinase capable of phosphorylating serine residues in the N-terminal of cJun and effecting its subsequent activation [
13]. JNK is only physiologically phosphorylated by the mitogen activated protein kinase (MAPK) kinases MKK4 and MKK7. However, in the ALCL cells, JNK is phosphorylated by NPM-ALK which in turn phosphorylates and activates cJun.
Activated cJun causes the transcriptional activation of cell cycle proteins (Cyclin D1, Cyclin D3, Cyclin A and Cyclin E) and the inhibition of tumor suppressors such as p53, p21
Cip1 and p16
Ink4. This is mediated through the recruitment of cAMP response element binding (CREB) protein (CBP) activator [
13]. JunB, another member of the Jun subset of AP–1 complex, is also a positive regulator of cell cycle progression [
14]. NPM-ALK also increases JunB expression through the mTOR pathway. mTOR is activated by the phosphoinositol 3- kinase/Akt pathways [
14,
15].
NPM-ALK has also been shown to act through the signal transducer and activator of transcription (STAT), principally STAT3 and STAT5 [
16-
19]. STAT3, for example, is constitutionally activated by NPM-ALK phosphorylation and is actively involved in the malignant transformation of NPM-ALK expressing lymphocytes [
17]. Activated STAT3 enhances the positive autocrine loop involving IL-6 and the IL-6 receptor (IL6R), which in turn up-regulates the expression of Bcl-xL and survivin, two anti-apoptotic factors [
18]. STAT5 activation also is thought to protect cells from apoptosis, likely from activation of anti-apoptotic factors such as A1 (or its human homologue, Bfl-1), Bcl-xL, pim-1 and oncostatin M [
16].
Another mechanism for NPM-ALK oncogenesis has been elucidated as occurring through the phosphorylation of p60
c-src. p60
c-src is a src kinase which plays specific roles in downstream effects of the T-cell receptor and causes hematopoietic growth factor independence specifically of IL-3 and granulocyte-macrophage colony stimulating factor (GM-CSF) [
20]. Activated Src kinase can lead to activation of NPM-ALK with downstream effects on PI3K/Akt. The effect of ALK on PLC-γ, Shc, IRS-1 and PI3K has been shown to be mediated through pleiotrophin, the ligand for the ALK receptor [
21].
Apart from the NPM-ALK mutation, TPM3-ALK mutation caused by the (1;2)(q25;p23) translocation fused ALK with TPM3 gene located on 1q25 [
22-
24]. TPM3 encodes a non-muscular tropomyosin protein. Tropomyosins are actin binding proteins that mediate the effect of ionized calcium on actin-myosin interaction in skeletal muscle cells [
22]. TPM3 has been shown to be fused with the NTRK1 tropomyosin receptor kinase in ALCL and papillary thyroid cancers [
22,
25,
26]. Another tropomyosin gene, TPM4, has also been found to be fused to the ALK gene in inflammatory myofibroblastic tumors (IMT) and other tumors [
24,
27-
30].
Another ALK mutation from fusion of ALK to the ATIC gene has been described [
31,
32]. ATIC gene encodes the 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (AICARFT/IMPCH) bifunctional enzyme. This enzyme catalyzes the last two steps in the purine synthesis pathway. The fusion gene becomes constitutionally active, leading to pathologic activation of ALK. Additional mutations identified in both solid tumors and hematological malignancies include MSN-ALK, MYH9-ALK, RANBP2–ALK, CARS-ALK, CLTCL-ALK [
3,
33-
44]. Rare mutations have been described in NSCLC, lymphoma, renal cell carcinoma and colon cancer [
37,
45-
58] (Tables
1 and
2).
Table 1
Chromosomal translocation and fusion proteins in solid tumors involving ALK gene
NSCLC | inv(2)(p21;p23) | EML4-ALK | 2-5 | |
| t(2;3)(p23;q21) | TFG-ALK | 2 | |
| t(2;10)(p23;p11) | KIF5B-ALK | <1 | |
| t(2;14)(p23;q32) | KLC1-ALK | <5 | |
| t(2;9)(p23;q31) | PTPN3-ALK | ND | |
IMT | t(1;2)(q25;p23) | TPM3-ALK | 0.5 | |
| t(2;19)(p23;p13) | TPM4-ALK | <5 | |
| t(2;17)(p23;q23) | CLTC-ALK | <5 | |
| inv(2)(p23;q35) | ALK-ATIC | <5 | |
| t(2;11;2)(p23;p15;q31) | CARS-ALK | <5 | |
| t(2;2)(p23;q13) | RANBP2-ALK | <5 | |
| inv(2)(p23;p15;q31) | RANBP2-ALK | <5 | |
| t(2;4)(p23;q21) | SEC31L1-ALK | <5 | |
BC | inv(2)(p21;p23) | EML4-ALK | <5 | |
CRC | inv(2)(p21;p23) | EML4-ALK | <5 | |
| t(2;2)(p23.3) | C2orf44-ALK | <5 | |
ESCC | t(2;19)(p23;p13) | TPM4-ALK | ND | |
RCC | t(2;10)(p23;q22) | VCL-ALK | ND | |
| t(1;2)(q25;p23) | TPM3–ALK | ND | |
| inv(2)(p21;p23) | EML4–ALK | ND | |
Table 2
Chromosomal translocations and fusion proteins in hematologic malignancies involving ALK gene
ALCL | t(2;5)(p23;q35) | NPM-ALK | 75-80 | |
| t(2;17)(p23;q25) | ALO17-ALK | <1 | |
| t(2;3)(p23;q21) | TFG-ALK | 2 | |
| t(2;X)(p32;q11-q12) | MSN-ALK | <1 | |
| t(1;2)(q25;p23) | TPM3-ALK | 12-18 | |
| t(2;19)(p23;p13) | TPM4-ALK | <1 | |
| inv(2)(p23;q35) | ATIC-ALK | 2 | |
| t(2;22)(p23;q11.2) | MYH9-ALK | <1 | |
| t(2;17)(p23;q23) | CLTCL-ALK | 2 | |
DLBCL | t(2;5)(p23;q35) | NPM-ALK | ND | |
| t(2;17)(p23;q23) | CLTC1-ALK | ND | |
| t(2;5)(p23.1;q35.3) | SQSTM1-ALK | ND | |
| ins(4)(2;4)(p23;q21) | SQSTM1-ALK | ND | |
| t(2;4)(p24;q21) | SEC31A-ALK | ND | |
HL | t(2;5)(p23;q35) | NPM-ALK | ND | |
EML4-ALK fusion gene was initially identified in 2007 in non-small cell lung cancer (NSCLC) [
59]. This has facilitated the development of the first ALK inhibitor, crizotinib [
60]. This mutation arises from inv(2)(p21p23) which leads to the fusion of echinoderm microtubule-associated protein like-4 (EML4) gene with ALK gene. The fusion protein plays a pivotal role in the malignant transformation of susceptible lung parenchyma [
61]. EML4 is a member of the EML protein (EMAP) family and plays an important role in the correct formation of microtubules [
62]. The EML4-ALK fusion kinase has an ALK fragment identical to the ALK fragment in NPM-ALK. This intracellular kinase is bound to the amino-terminal coiled-coil domain of EML4 and is thought to be responsible for the transforming activity of the fusion protein [
23,
63-
65].
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DL and CI designed the study and drafted the manuscript. All authors have contributed to data preparation, drafting and revising the manuscripts. All authors have read and approved the final manuscript.